Success Metrics

Clinical Success Rate
75.3%

Based on 286 completed trials

Completion Rate
75%(286/380)
Active Trials
197(28%)
Results Posted
82%(234 trials)
Terminated
94(13%)

Phase Distribution

Ph early_phase_1
4
1%
Ph not_applicable
11
2%
Ph phase_3
158
23%
Ph phase_1
174
25%
Ph phase_2
333
48%
Ph phase_4
10
1%

Phase Distribution

178

Early Stage

333

Mid Stage

168

Late Stage

Phase Distribution690 total trials
Early Phase 1First-in-human
4(0.6%)
Phase 1Safety & dosage
174(25.2%)
Phase 2Efficacy & side effects
333(48.3%)
Phase 3Large-scale testing
158(22.9%)
Phase 4Post-market surveillance
10(1.4%)
N/ANon-phased studies
11(1.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

69.4%

286 of 412 finished

Non-Completion Rate

30.6%

126 ended early

Currently Active

197

trials recruiting

Total Trials

699

all time

Status Distribution
Active(218)
Completed(286)
Terminated(126)
Other(69)

Detailed Status

Completed286
Recruiting117
Terminated94
Active, not recruiting80
unknown67
Withdrawn32

Development Timeline

Analytics

Development Status

Total Trials
699
Active
197
Success Rate
75.3%
Most Advanced
Phase 4

Trials by Phase

Early Phase 14 (0.6%)
Phase 1174 (25.2%)
Phase 2333 (48.3%)
Phase 3158 (22.9%)
Phase 410 (1.4%)
N/A11 (1.6%)

Trials by Status

not_yet_recruiting203%
completed28641%
terminated9413%
enrolling_by_invitation10%
suspended20%
withdrawn325%
recruiting11717%
active_not_recruiting8011%
unknown6710%

Recent Activity

Clinical Trials (699)

Showing 20 of 699 trialsScroll for more
NCT07100080Phase 2

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Recruiting
NCT06694454Phase 1

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Not Yet Recruiting
NCT07005102Phase 2

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Recruiting
NCT06151574Phase 3

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Active Not Recruiting
NCT06096844Phase 3

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

Recruiting
NCT06712316Phase 2

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Recruiting
NCT05001880Phase 2

Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma

Recruiting
NCT06741644Phase 1

A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

Recruiting
NCT06946797Phase 2

A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)

Recruiting
NCT05635708Phase 2

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

Active Not Recruiting
NCT06623422Phase 3

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Recruiting
NCT05382559Phase 1

A Study of ASP3082 in Adults With Advanced Solid Tumors

Recruiting
NCT05059522Phase 3

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Active Not Recruiting
NCT07252739Phase 2

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Recruiting
NCT06459180Phase 3

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

Recruiting
NCT04538664Phase 3

A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

Active Not Recruiting
NCT07524257Phase 3

ResQ1010-NSCLC: NAI + Chemoimmunotherapy vs Chemoimmunotherapy for First-Line Advanced/Metastatic NSCLC

Not Yet Recruiting
NCT06793215Phase 3

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Recruiting
NCT06448754Phase 2

Volrustomig Priming Regimens Exploratory Phase II Platform Study

Recruiting
NCT02194738Not Applicable

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Active Not Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
699